Clinical trials: Plaque Psoriasis Subjects
Psoriasis
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
The main purpose of this study is to evaluate the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in participants who have been previously enrolled in an applicable Phase 3 psoriasis study.
- Trial name
- POETYK PSO-LTE (NCT04036435)
- Testing
- BMS-986165
- Where
- 302 sites in United States, Australia and 18 more
- Volunteers
- 1,466 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis
A study to evaluate the safety and efficacy of adalimumab in Chinese subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT01646073
- Testing
- Adalimumab
- Where
- 16 sites in China
- Volunteers
- 425 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Plaque Psoriasis
Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis
This is an open-label Phase III clinical study to evaluate the long-term safety and efficacy of AK101 injection in subjects with moderate-to-severe plaque psoriasis.
- Trial name
- NCT05509361
- Testing
- AK101 injection SC
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Akeso
Plaque Psoriasis
Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast
To evaluate the efficacy of etanercept in adults with moderate to severe plaque psoriasis who have failed therapy with apremilast (Otezla).
- Trial name
- NCT02749370
- Testing
- Etanercept
- Where
- 22 sites in United States
- Volunteers
- 80 people
- Sponsor
- Amgen
Moderate to Severe Plaque-type Psoriasis
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
This was an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab.
- Trial name
- NCT01544595
- Testing
- Secukinumab (AIN457)
- Where
- 182 sites in United States, Argentina and 24 more
- Volunteers
- 1,147 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06108544
- Testing
- TAK-279, Apremilast
- Where
- 217 sites in United States, Argentina and 14 more
- Volunteers
- 1,108 people
- Sponsor
- Takeda
Psoriasis
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
The study will investigate the efficacy and safety compared to placebo and the safety compared to ustekinumab of brodalumab in adolescents with moderate to severe plaque psoriasis.
- Trial name
- EMBRACE 1 (NCT04305327)
- Testing
- Brodalumab, Ustekinumab
- Where
- 35 sites in Belgium, France and 6 more
- Volunteers
- 12 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis
This is a phase 1, open label, single arm study in which ARQ-151 cream 0.3% is applied QD for 2 weeks to adolescent subjects with chronic plaque psoriasis involving at least 10% body surface area (BSA) and adult subjects with…
- Trial name
- MUSE (NCT04279119)
- Testing
- ARQ-151- cream 0.3%
- Where
- 12 sites in United States
- Volunteers
- 26 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Plaque Psoriasis
Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis
The purpose of this study is to learn more about the immune response to etanercept produced using a modified process in patients with plaque psoriasis.
- Trial name
- NCT02274792
- Testing
- Etanercept
- Where
- 45 sites in United States, Canada
- Volunteers
- 132 people
- Sponsor
- Amgen
Plaque Psoriasis
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to…
- Trial name
- NCT05073315
- Testing
- Adalimumab, ABP 501
- Where
- 88 sites in United States, Canada and 4 more
- Volunteers
- 425 people
- Sponsor
- Amgen
Psoriasis
A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis
This is a Phase Ib clinical study of multiple dose escalation of AK111 in subjects with moderate-to-severe plaque psoriasis
- Trial name
- NCT05504317
- Testing
- AK111
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Akeso
Psoriasis
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
The objective of this Phase 2 trial is to determine the efficacy and safety of LYC-30937-EC in patients with moderate plaque-type psoriasis.
- Trial name
- NCT02872285
- Testing
- Drug: LYC-30937-EC
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- Lycera Corp.
Plaque Psoriasis
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis.
- Trial name
- AMAGINE-3 (NCT01708629)
- Testing
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab
- Where
- 157 sites in United States, Australia and 9 more
- Volunteers
- 1,881 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
The purpose of this study is to explore the efficacy and safety of multiple, escalating doses of ASP015K when compared to placebo in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT01096862
- Testing
- peficitinib
- Where
- 11 sites in United States
- Volunteers
- 124 people
- Sponsor
- Astellas Pharma Inc
Plaque Psoriasis
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of 12 weeks of treatment with Apo805K1 in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01483924
- Testing
- Apo805K1
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- ApoPharma
Plaque Psoriasis
Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis
This study is designed to evaluate the efficacy and safety of Prurisol using three different oral daily dose regimens administered to subjects with active mild to moderate chronic plaque psoriasis.
- Trial name
- NCT02494479
- Testing
- Prurisol
- Where
- 9 sites in United States
- Volunteers
- 115 people
- Sponsor
- Cellceutix Corporation
Psoriasis
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients with moderate to severe psoriasis.
- Trial name
- NCT01090427
- Testing
- Ustekinumab - Half-Standard Dosage, Ustekinumab - Standard Dosage
- Where
- 50 sites in Belgium, Canada and 8 more
- Volunteers
- 110 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.
- Trial name
- NCT03210961
- Testing
- PF-06826647 tablet, PF-06826647 oral suspension
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Pfizer
Psoriasis
Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00645905
- Testing
- adalimumab
- Volunteers
- 148 people
- Sponsor
- Abbott
Plaque Psoriasis
Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis
Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis.
- Trial name
- NCT02201524
- Testing
- PF-04965842
- Where
- 45 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Pfizer